Belgium: Biopharmaceuticals Kaneka Eurogentec to Construct Biologics Manufacturing Facility

Editor: Alexander Stark

Kaneka Eurogentec announced that the site expansion in Belgium would allow the GMP production of kg-scale plasmid DNA and recombinant protein intended for clinical phases and commercialization.

Related Vendors

The expansion of Kaneka Eurogentec's facility will result in the hiring of 40 full time scientific staff trained in the production of GMP therapeutic products.
The expansion of Kaneka Eurogentec's facility will result in the hiring of 40 full time scientific staff trained in the production of GMP therapeutic products.
(Source: CC0 Pixabay)

Seraing/Belgium — Kaneka Eurogentec announced that it will construct a new state of-the-art GMP facility adjacent to its current facility and equipped with a 2,200 liter fermenter.

The multi-product facility will include the capability for large scale production using the company's own technologies such as the production of complex proteins by secretion from yeasts and the production of kilo-scale plasmid DNA for viral and non-viral gene and cell therapies.

This expansion will be complementary to the current capabilities and together will provide small and industrial scale production.

Construction is expected to start in autumn of 2017. The expansion will result in the hiring of 40 full time scientific staff trained in the production of GMP therapeutic products.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent

(ID:44893558)